Gonorrhea Market to Register Stunning Growth During the Forecast Period (2023-2032) - DelveInsight | Key Companies - Evofem Biosciences, GlaxoSmithKline, Entasis Therapeutics, Alopexx, Nobelex, TherapyX, AchilleS Vaccines, Recce Pharmaceuticals, VenatoRx

DelveInsight's "Gonorrhea Market Insights, Epidemiology, and Market Forecast 2032" report provides comprehensive insights into the disease landscape, encompassing historical and forecasted epidemiological data, along with an analysis of the Gonorrhea market. The report offers valuable information regarding market size, share, emerging trends, and growth prospects across the seven major markets (7MM), including the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Additionally, the report delves into emerging therapies for Gonorrhea, providing insights into current treatment methodologies, individual therapy market shares, and a comprehensive evaluation of the market size, spanning from 2019 to 2032. It assesses the existing treatment practices and algorithms for Gonorrhea, investigates the key factors influencing market growth, identifies barriers, and highlights unmet medical needs. This comprehensive analysis aims to pinpoint opportunities and gauge the market's inherent potential to address the critical aspects of Gonorrhea management.

Learn How the Gonorrhea Market is Evolving with the Ongoing Developments @ Gonorrhea Market Outlook 

Gonorrhea: An Overview

Gonorrhoea is a sexually transmitted infection caused by the Neisseria gonorrhoeae. It tends to infect warm and moist areas of the body like the urethra, eyes, throat, anus, vagina, and female reproductive tract. Urethral infections in men and urogenital infections in women are the main presenting features, but a broad spectrum of clinical presentations can occur, including systemic dissemination with fever and skin and joint involvement. Throat and anorectal infections also occur.

Gonorrhoea is transmitted through sexual contact, including sex without using a condom, vaginal intercourse, anal and oral sex. The infection can also be transmitted from mother to child during childbirth.

Management of gonorrhea is entirely based on the use of antibiotics. Gonorrhoea is treated with antibiotics called cephalosporins. These include: ceftriaxone, usually given by injection and is the preferred treatment, and cefixime, usually given orally with another antibiotic, azithromycin, but only when ceftriaxone is not feasible. Most cases of gonorrhea can be prevented with consistent and correct condom use in every sexual encounter. Antibiotic eye ointment is recommended for newborns to prevent gonococcal eye infections. There are no specific vaccines for the prevention of gonorrhea, however, companies are trying to develop some vaccines.

Gonorrhea Market Key Facts

• The World Health Organization (WHO) estimates that in 2012, 78 million new cases occurred among adolescents and adults aged 15–49 years worldwide, with a global incidence rate of 19 per 1000 females and 24 per 1000 males.
• According to the Annual Epidemiological Report for 2019 of the European Centre for Disease Prevention and Control (2019), a total of 117,881 confirmed cases of gonorrhea were reported by 28 EU/EEA Member States.
• According to Rowley et al. (2016), in 2016, an estimated 87 million incident cases occurred among persons aged 15–49 years worldwide, with an incidence rate of 20 cases/1000 women and 26/1000 men.

Get Exclusive Data and Key Insights Shaping the Market Dynamics @ Gonorrhea Market Trends

Gonorrhea Therapeutics Analysis

The use of antibiotics is the mainstay treatment for gonorrhea. True to its genetically plastic lifestyle, Neisseria gonorrhoeae has a remarkable ability to develop resistance to antibiotics. Due to this increase in the number of cases of anti-microbial resistance, there is a fall in the treatment of antibiotics. The management of gonorrhea is mainly based on pharmacotherapy, both monotherapy and combination therapy (dual therapy) are being used.

Combination therapy entails the utilization of multiple medications for the purpose of treating a particular condition. This particular category predominantly encompasses a blend of diverse drugs. The primary advantage of combination therapy, in contrast to monotherapy, lies in its efficacy in combating bacterial infections such as gonorrhea. This is due to the limited capacity of the bacterial strain to develop resistance against the drugs, as the bacterium is less likely to acquire resistance to multiple drugs administered concurrently. The recommended initial treatment regimen for gonorrhea is dual therapy, involving the administration of ceftriaxone and azithromycin.

To improve the treatment scenario, Several major pharma and biotech companies are developing therapies for Gonorrhea. The current pipeline of Gonorrhea consists of a few drugs and vaccines, such as GSK2140944 (gepotidacin), GSK4348413, and others. So there is a wide opportunity available for key market players to enter the market. Ongoing awareness and research may increase the market size and improve the treatment outlook. Currently, GlaxoSmithKline is leading the therapeutics market with its Gonorrhea drug candidates in the most advanced stage of clinical development.

Gonorrhea Therapeutic Advancements and Emerging Treatments

• Gonorrhea Clinical Trial Progression and Key Companies: The market is set to experience significant growth, driven by the progression of emerging therapies expected for launch between 2023 and 2032. Pioneering companies, including Evofem Biosciences, GlaxoSmithKline, Entasis Therapeutics, Alopexx Pharmaceuticals, Nobelex Biotech, Summit Therapeutics, TherapyX, AchilleS Vaccines, Recce Pharmaceuticals, VenatoRx Pharmaceuticals, and many others, are actively engaged in developing novel drugs for potential market entry.
• Gonorrhea Emerging and Marketed Therapies: Ongoing research and development activities are fostering the introduction of innovative therapies designed to address the signs and symptoms of Gonorrhea. Some of the emerging therapies in the pipeline include SMT-571 (Summit Therapeutics), F 598 (Alopexx Pharmaceuticals), EVO100 (Evofem Biosciences), Gepotidacin (GlaxoSmithKline), Zoliflodacin (Entasis Therapeutics), and many others.

Recent Developments in the Gonorrhea Market

• On 27 June 2023, GSK plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has granted a Fast Track designation for its Neisseria gonorrhoeae investigational vaccine (NgG). The vaccine candidate is currently in an ongoing Phase II trial and aims to demonstrate proof of concept by assessing the efficacy of the NgG vaccine in healthy adults, 18 to 50 years of age, considered at risk of gonorrhea.
• On 11 October, 2022, Evofem Biosciences, Inc. (OTCQB: EVFM) announced that the recently completed Phase 3 EVOGUARD clinical trial evaluating EVO100 for the prevention of chlamydia and gonorrhea infection in women did not achieve its endpoints.

Discover Significant Progress and Start Making Informed Decisions @ Clinical, Commercial, and Regulatory Activities in the Gonorrhea Market

Gonorrhea Market Growth Factors and Associated Trends

The Gonorrhea market exhibits a complex interplay of drivers and barriers that significantly shape its trajectory. Drivers stimulating market growth include the increasing prevalence of antibiotic-resistant strains of Neisseria gonorrhoeae, the bacterium causing Gonorrhea, which necessitates the development of novel treatment options. Additionally, heightened awareness and proactive initiatives for sexually transmitted infection (STI) testing and diagnosis propel market expansion, fostering a more comprehensive approach to disease management and reducing transmission rates. Moreover, advancements in research and development, particularly in the realm of vaccines and alternative therapies, present promising avenues for addressing the challenges posed by antibiotic resistance. 

However, several barriers impede market growth, notably the lack of comprehensive screening programs, particularly in resource-constrained regions, leading to underdiagnosis and inadequate treatment. Stigma and social barriers surrounding STIs also hinder individuals from seeking timely medical care, contributing to the spread of the disease. Furthermore, the intricate nature of the bacterium's biology and mechanisms of resistance poses a significant challenge in developing effective treatment options. Overcoming these barriers requires concerted efforts across healthcare sectors, increased public awareness campaigns, expanded access to screening and treatment, and sustained investment in research for innovative solutions.

Gonorrhea Market

The report's market outlook section offers a comprehensive understanding of the historical, present, and projected market size. It scrutinizes the influence of existing and upcoming pipeline therapies for Gonorrhea. Moreover, it conducts a thorough evaluation of the factors driving and hindering the Gonorrhea market, highlighting unmet needs and emerging technologies poised to shape the market's dynamics in the foreseeable future.

The report meticulously outlines the market trends concerning each marketed Gonorrhea drug and mid to late-stage pipeline therapies. This evaluation gauges their impact by considering various aspects such as the annual cost of therapy, Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competitive landscape among therapies, brand value, and their collective influence on the market dynamics.

Discover the Anticipated Evolution and Growth of the Market @ Gonorrhea Therapeutics Market Forecast

Gonorrhea Epidemiology Assessment

The epidemiology section offers valuable insights into the historical, present, and anticipated trends in Gonorrhea epidemiology across the seven major countries (7MM) from 2019 to 2032. This section aims to identify the factors contributing to current and projected Gonorrhea epidemiological patterns by examining diverse studies and research findings. Additionally, it furnishes a comprehensive analysis of diagnosed and prevalent patient populations, and future projections, and incorporates perspectives from key opinion leaders to enrich the understanding of this disease landscape.

The Report Covers the Gonorrhea Epidemiology, Segmented as -

• Total Incident Cases of Gonorrhoea in the 7MM [2019-2032]
• Gender-specific Incident Cases of Gonorrhoea (Allergic and Nonallergic) in the 7MM [2019-2032] 
• Age-specific Incident Cases of Gonorrhoea in the 7MM [2019-2032]
• Treatable Cases of Gonorrhoea in the 7MM [2019-2032]

Gonorrhea Drugs Uptake and Pipeline Development Activities

The drug uptake section concentrates on evaluating the adoption rate of newly launched or upcoming potential drugs within the Gonorrhea market during the study period. This analysis encompasses the assessment of drug uptake in the Gonorrhea market, patient adoption across different therapies, and the sales performance of each drug. Furthermore, the therapeutics assessment section facilitates a comprehensive comprehension of market dynamics by examining drug sales trends, identifying drugs with the highest adoption rates, and elucidating the reasons contributing to the widespread use of specific medications. Additionally, it conducts comparative analyses among Gonorrhea drugs, considering their sales performance and respective market shares.

The report encompasses comprehensive coverage of ongoing Gonorrhea pipeline development initiatives. It furnishes valuable insights into diverse therapeutic candidates at various developmental stages, elucidating the significant companies actively engaged in creating targeted treatments for Gonorrhea. Moreover, it conducts an in-depth analysis of recent advancements, including collaborations, acquisitions, mergers, licensing details, and patent information, providing a holistic view of emerging therapies within the field.

Reports Key Features and Analysis

• Study Period - 2019-32
• Forecast Period - 2023-32
• Geography Coverage - 7MM (United States, EU4 [Germany, Spain, Italy, France], the United Kingdom, and Japan)
• Market Size (by 2032) and Expected CAGR - Download the Sample PDF
• Major Players Shaping the Market Outlook - Evofem Biosciences, GlaxoSmithKline, Entasis Therapeutics, Alopexx Pharmaceuticals, Nobelex Biotech, Summit Therapeutics, TherapyX, AchilleS Vaccines, Recce Pharmaceuticals, VenatoRx Pharmaceuticals, and many others.
• Emerging and Marketed Therapies Analyzed in the Report - SMT-571 (Summit Therapeutics), F 598 (Alopexx Pharmaceuticals), EVO100 (Evofem Biosciences), Gepotidacin (GlaxoSmithKline), Zoliflodacin (Entasis Therapeutics), and many others.

For In-depth Insights, Key Report Offerings and TOC; Access the Sample PDF File @ Gonorrhea Therapeutics Market Outlook and Forecast

Related Reports:

• Gonorrhea Epidemiology Forecast

The Gonorrhea Epidemiology Forecast report delivers an in-depth understanding of Gonorrhea, and historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

• Gonorrhea Pipeline Insight

The Gonorrhea Pipeline Insight report provides comprehensive insights about major pharma and biotech companies and emerging drugs in the Gonorrhea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

Healthcare Consulting and Market Research Services by DelveInsight

Unlock key insights and innovation in the healthcare industry with our cutting-edge market research services, paving the way for informed decisions and competitive advantage in this rapidly evolving industry @ Medical Device Consulting Services

Explore Our Success Story on Building an Interactive Competitive Intelligence Dashboard for HR+ HER2- Breast Cancer Market Landscape. Download our Oncology Competitive Intelligence Case Study!

About DelveInsight:

DelveInsight is a prominent business consultant and market research firm specializing in the life sciences sector. With a focus on supporting pharmaceutical companies, DelveInsight provides end-to-end solutions to enhance their performance.

 Contact Information:

Shruti Thakur (Manager, Marketing and IB)

info@delveinsight.com

www.delveinsight.com

Connect with DelveInsight: LinkedIn | Facebook | Twitter